AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million
March 4, 2026
IDEAYA Announces Pricing of Public Offering of Common Stock
July 8, 2021
Related Post
-
-
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
March 4, 2026
-
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
March 4, 2026
-
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
March 4, 2026